

Kymab's Expanded Access Policy for KY1005

Kymab is dedicated to developing novel human antibody-based therapeutics across a broad range of indications including immune mediated diseases.

Expanded access permits the use of an investigational therapy in patients with a serious or life-threatening illness when no satisfactory preventive or treatment options are available, and the patient is ineligible to participate in a clinical trial. Kymab understands and respects the need for appropriately managed expanded access program(s), and accordingly, this policy has been generated.

The following criteria are informed by regulatory guidelines for when expanded access may be made available to an investigational product on a case-by-case basis for individual patients:

- Ongoing or planned clinical studies are not available to the patient, including lack of access due to geographical location of potential clinical trial sites;
- Significant evidence exists that supports both the safety and the efficacy of the investigational drug for the indication;
- The potential benefits to the particular patient seeking access to the investigational drug outweigh the potential risks to the patient;
- An adequate supply of the investigational drug exists;
- All necessary regulatory/institutional approvals have been obtained to allow drug administration, and
- The request for expanded access has been made by a qualified health care provider with expertise appropriate for the administration of the drug and for monitoring and managing the patient.

KY1005 is currently in early clinical development. Kymab believes that the most appropriate way to ensure appropriate use of KY1005 at this stage in development is via approved clinical trials. The initial clinical trial(s) will permit the effective generation of safety and efficacy data for KY1005 which, when shared with the Regulatory Authorities will further guide the decision making regarding its safe and effective use in an expanded access program.

At this time, therefore, Kymab will not offer expanded access and will not currently accept expanded access requests for KY1005. Information regarding KY1005's clinical trials will be made available at <https://clinicaltrials.gov/>.

If you have additional questions, please speak with your health care provider or contact KY1005ExpandedAccess@Kymab.com. Kymab will typically respond to requests sent to this email address within five business days.

In accordance with the US 21st Century Cures Act, Kymab may revise this policy at any time.